Q1 2020 13F Holders as of 3/31/2020
-
Type / Class
-
Equity / Common Stock, par value $0.001
-
Shares outstanding
-
67.8M
-
Number of holders
-
29
-
Total 13F shares, excl. options
-
3.91M
-
Shares change
-
+45.8K
-
Total reported value, excl. options
-
$5.82M
-
Value change
-
-$78.4K
-
Put/Call ratio
-
0.33
-
Number of buys
-
11
-
Number of sells
-
-12
-
Price
-
$1.66
Significant Holders of Celldex Therapeutics, Inc. - Common Stock, par value $0.001 (CLDX) as of Q1 2020
41 filings reported holding CLDX - Celldex Therapeutics, Inc. - Common Stock, par value $0.001 as of Q1 2020.
Celldex Therapeutics, Inc. - Common Stock, par value $0.001 (CLDX) has 29 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 3.91M shares
of 67.8M outstanding shares and own 5.77% of the company stock.
Largest 10 shareholders include RENAISSANCE TECHNOLOGIES LLC (1.17M shares), VANGUARD GROUP INC (538K shares), Cresset Asset Management, LLC (458K shares), TSP Capital Management Group, LLC (410K shares), DIMENSIONAL FUND ADVISORS LP (346K shares), BlackRock Inc. (344K shares), ACADIAN ASSET MANAGEMENT LLC (299K shares), GEODE CAPITAL MANAGEMENT, LLC (104K shares), BRIDGEWAY CAPITAL MANAGEMENT INC (50.2K shares), and CREDIT SUISSE AG/ (35K shares).
This table shows the top 29 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.